Search results
Jun 24, 2024 · Biocon is a leading biotech company that develops and manufactures biosimilars, generics, APIs and novel biologics. It has a global presence, a strong patent portfolio and a social responsibility agenda.
- Products
Biocon is addressing global medical needs through a...
- Careers
Careers - Biocon - India's largest biopharmaceutical company
- About Us
A global biopharmaceutical company changing patients’ lives...
- Businesses
Biocon’s business strategy of delivering affordable...
- Investors
Biocon is a unique global biopharmaceutical company changing...
- Responsibility
Biocon academy, is a premier center of excellence for...
- News
News - Biocon - India's largest biopharmaceutical company
- Key Therapeutic Areas
At Biocon, our focus is on the three key therapeutic areas –...
- Generics
Generic Formulations, API's (Cardiology, Anti-Diabetics,...
- Biosimilars
Biosimilars - Biocon - India's largest biopharmaceutical...
- Products
Biocon Limited is an Indian biopharmaceutical company based in Bangalore. It was founded by Kiran Mazumdar-Shaw in 1978. The company manufactures generic active pharmaceutical ingredients (APIs) that are sold in approximately 120 countries, including the United States and Europe.
Biocon is a pioneer in biotechnology in India, with a mission to provide affordable and innovative medicines for diabetes, cancer and autoimmune diseases. It has four global businesses: generics, biosimilars, research services and novel biologics, and operates in over 120 countries.
Biocon evolved from manufacturing speciality enzymes to pharmaceuticals like statins and immunosuppressants, to discovering, developing, and producing life-saving biotherapeutics. It has been a journey of endurance over several decades - from being the ‘first Indian company’ to win U.S. Food & Drugs Administration (FDA) approval for ...
BioconBusinessesRecommended SitesRecommended SitesHome ...Our Growth Accelerators ...ABLE Karnataka Vision ...ABLE Karnataka Vision ...© 2018, Biocon. All Rights ReservedMay 21, 2024 · Biocon Biologics has commercialized eight biosimilars in key emerging markets and advanced markets like U.S., Europe, Australia, Canada, and Japan. The Company has a pipeline of 20 biosimilar ...
May 20, 2024 · The U.S. Food and Drug Administration (FDA) on Monday approved two close copies of Regeneron Pharmaceuticals' Eylea, its first-ever clearance to biosimilar versions of the blockbuster eye...